- Home
- BIAF vs TLPH Comparison
BIAF vs TLPH Comparison
Compare BIAF & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- TLPH
- Stock Information
- Founded
- BIAF 2014
- TLPH 2005
- Country
- BIAF United States
- TLPH United States
- Employees
- BIAF N/A
- TLPH N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- TLPH Health Care
- Exchange
- BIAF Nasdaq
- TLPH Nasdaq
- Market Cap
- BIAF 12.2M
- TLPH 10.6M
- IPO Year
- BIAF 2022
- TLPH 2011
- Fundamental
- Price
- BIAF $0.29
- TLPH $0.47
- Analyst Decision
- BIAF Hold
- TLPH Strong Buy
- Analyst Count
- BIAF 1
- TLPH 1
- Target Price
- BIAF N/A
- TLPH $6.00
- AVG Volume (30 Days)
- BIAF 11.2M
- TLPH 44.5K
- Earning Date
- BIAF 08-13-2025
- TLPH 08-13-2025
- Dividend Yield
- BIAF N/A
- TLPH N/A
- EPS Growth
- BIAF N/A
- TLPH N/A
- EPS
- BIAF N/A
- TLPH N/A
- Revenue
- BIAF $8,809,228.00
- TLPH $27,000.00
- Revenue This Year
- BIAF N/A
- TLPH N/A
- Revenue Next Year
- BIAF $20.00
- TLPH $14,533.26
- P/E Ratio
- BIAF N/A
- TLPH N/A
- Revenue Growth
- BIAF 78.40
- TLPH N/A
- 52 Week Low
- BIAF $0.16
- TLPH $0.43
- 52 Week High
- BIAF $2.99
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- BIAF 50.96
- TLPH 35.99
- Support Level
- BIAF $0.22
- TLPH $0.45
- Resistance Level
- BIAF $0.46
- TLPH $0.52
- Average True Range (ATR)
- BIAF 0.04
- TLPH 0.03
- MACD
- BIAF 0.01
- TLPH -0.01
- Stochastic Oscillator
- BIAF 30.51
- TLPH 11.11
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.